Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9262)
All Articles published online
|
Publishing Process of This Article
|
Dec 15, 2015 (publication date) through May 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Klieser E, Swierczynski S, Mayr C, Schmidt J, Neureiter D, Kiesslich T, Illig R. Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy. World J Gastrointest Oncol 2015; 7(12): 473-483 [PMID: 26691388 DOI: 10.4251/wjgo.v7.i12.473] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v7/i12/473.htm |
| Number | Citing Articles |
| 1 |
Pritha Bhattacharjee, Somnath Paul, Sandip Bhattacharjee, Ashok K. Giri, Pritha Bhattacharjee. Association of H3K79 monomethylation (an epigenetic signature) with arsenic-induced skin lesions. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2018; 807: 1 doi: 10.1016/j.mrfmmm.2017.11.001
|
| 2 |
Eckhard Klieser, Romana Urbas, Stefan Swierczynski, Stefan Stättner, Florian Primavesi, Tarkan Jäger, Christian Mayr, Tobias Kiesslich, Pietro Di Fazio, Katharina Helm, Daniel Neureiter. HDAC-Linked “Proliferative” miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors. International Journal of Molecular Sciences 2018; 19(9): 2781 doi: 10.3390/ijms19092781
|
| 3 |
Bingyi Zhou, Deliang Liu, Yuyong Tan. Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.719390
|
| 4 |
Shelby M. Knoche, Gabrielle L. Brumfield, Benjamin T. Goetz, Bailee H. Sliker, Alaina C. Larson, Madeline T. Olson, Brittany J. Poelaert, Audrey Bavari, Ying Yan, Jennifer D. Black, Joyce C. Solheim, Ajay Pratap Singh. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. PLOS ONE 2022; 17(9): e0273518 doi: 10.1371/journal.pone.0273518
|
| 5 |
Asmaa Elrakaybi, Dietrich A. Ruess, Michael Lübbert, Michael Quante, Heiko Becker. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. Cancers 2022; 14(23): 5926 doi: 10.3390/cancers14235926
|
| 6 |
Max M. Träger, Sameer A. Dhayat. Epigenetics of epithelial‐to‐mesenchymal transition in pancreatic carcinoma. International Journal of Cancer 2017; 141(1): 24 doi: 10.1002/ijc.30626
|
| 7 |
Richard S. Laschanzky, Lisa E. Humphrey, Jihyun Ma, Lynette M. Smith, Thomas J. Enke, Surendra K. Shukla, Aneesha Dasgupta, Pankaj K. Singh, Gillian M. Howell, Michael G. Brattain, Quan P. Ly, Adrian R. Black, Jennifer D. Black. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Cancers 2019; 11(9): 1327 doi: 10.3390/cancers11091327
|
| 8 |
Chandra Maharjan, Po Ear, Catherine Tran, James Howe, Chandrikha Chandrasekharan, Dawn Quelle. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers 2021; 13(20): 5117 doi: 10.3390/cancers13205117
|
| 9 |
Xue-Song Xiang, Peng-Cheng Li, Wen-Quan Wang, Liang Liu. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022; 1877(1): 188676 doi: 10.1016/j.bbcan.2022.188676
|
| 10 |
Eckhard Klieser, Romana Urbas, Stefan Stättner, Florian Primavesi, Tarkan Jäger, Adam Dinnewitzer, Christian Mayr, Tobias Kiesslich, Klaus Holzmann, Pietro Di Fazio, Daniel Neureiter, Stefan Swierczynski. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Human Pathology 2017; 65: 41 doi: 10.1016/j.humpath.2017.02.009
|
| 11 |
M. Borghesani, L. Gervaso, C.A. Cella, L. Benini, D. Ciardiello, L. Algeri, A. Ferrero, C. Valenza, L. Guidi, MG. Zampino, F. Spada, N. Fazio. Promising targetable biomarkers in pancreatic neuroendocrine tumours. Expert Review of Endocrinology & Metabolism 2023; 18(5): 387 doi: 10.1080/17446651.2023.2248239
|
| 12 |
Fataneh Karandish, James Froberg, Pawel Borowicz, John C. Wilkinson, Yongki Choi, Sanku Mallik. Peptide-targeted, stimuli-responsive polymersomes for delivering a cancer stemness inhibitor to cancer stem cell microtumors. Colloids and Surfaces B: Biointerfaces 2018; 163: 225 doi: 10.1016/j.colsurfb.2017.12.036
|
| 13 |
Alexander Arlt, Heiner Schäfer. Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma. Expert Opinion on Investigational Drugs 2016; 25(11): 1251 doi: 10.1080/13543784.2016.1240167
|
| 14 |
Leonel Pekarek, Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel A. Saez, Ines Barquero-Pozanco, Laura del Hierro-Marlasca, Patricia de Castro Martinez, Adoración Romero-Bazán, Miguel A. Alvarez-Mon, Jorge Monserrat, Natalio García-Honduvilla, Julia Buján, Melchor Alvarez-Mon, Luis G. Guijarro, Miguel A. Ortega. Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer. Cancers 2022; 14(8): 1866 doi: 10.3390/cancers14081866
|
| 15 |
Magdalena Mizerska-Kowalska, Adrianna Sławińska-Brych, Emilia Niedziela, Viktor Brodovskiy, Barbara Zdzisińska. Alpha Ketoglutarate Downregulates the Neutral Endopeptidase and Enhances the Growth Inhibitory Activity of Thiorphan in Highly Aggressive Osteosarcoma Cells. Molecules 2022; 28(1): 97 doi: 10.3390/molecules28010097
|
| 16 |
Judy S. Crabtree. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.901435
|
| 17 |
Sayedeh Azimeh Hosseini, Mahdi Ghatrehsamani, Hajar Yaghoobi, Fatemeh Elahian, Seyed Abbas Mirzaei. Epigenetic disruption of histone deacetylase-2 accelerated apoptotic signaling and retarded malignancy in gastric cells. Epigenomics 2024; 16(5): 277 doi: 10.2217/epi-2023-0350
|
| 18 |
Sathish Kumar Mungamuri. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. 2019; : 133 doi: 10.1016/B978-0-12-817661-0.00009-3
|
| 19 |
Somayeh Layeghi-Ghalehsoukhteh, Shreoshi Pal Choudhuri, Ozhan Ocal, Yalda Zolghadri, Victor Pashkov, Hanspeter Niederstrasser, Bruce A. Posner, Havish S. Kantheti, Ana C. Azevedo-Pouly, Huocong Huang, Luc Girard, Raymond J. MacDonald, Rolf A. Brekken, Thomas M. Wilkie. Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-77373-8
|
| 20 |
Mao-Hua Cai, Xiao-Gang Xu, Shi-Li Yan, Ze Sun, Yin Ying, Bai-Kui Wang, Yue-Xing Tu. Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-20004-0
|
| 21 |
Feda Hamdan, Steven Johnsen. Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic Cancer. Epigenomes 2018; 2(2): 8 doi: 10.3390/epigenomes2020008
|
| 22 |
Claudia Geismann, Alexander Arlt. Coming in the Air: Hypoxia Meets Epigenetics in Pancreatic Cancer. Cells 2020; 9(11): 2353 doi: 10.3390/cells9112353
|
| 23 |
Hong Xiang, Hao Yu, Qi Zhou, Yu Wu, Jiaqi Ren, Zirui Zhao, Xufeng Tao, Deshi Dong. Macrophages: A rising star in immunotherapy for chronic pancreatitis. Pharmacological Research 2022; 185: 106508 doi: 10.1016/j.phrs.2022.106508
|
| 24 |
Pranita Atri, Ashu Shah, Gopalakrishnan Natarajan, Satyanarayana Rachagani, Sanchita Rauth, Koelina Ganguly, Joseph Carmicheal, Dario Ghersi, Jesse L. Cox, Lynette M. Smith, Maneesh Jain, Sushil Kumar, Moorthy P. Ponnusamy, Parthasarathy Seshacharyulu, Surinder K. Batra. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. npj Precision Oncology 2024; 8(1) doi: 10.1038/s41698-024-00562-5
|